Synthesis of Four Heterocyclic Drug Molecules Repurposed for COVID-19
Mini-Reviews in Organic Chemistry
; 19(2):180-187, 2022.
Article
in English
| Scopus | ID: covidwho-1674142
ABSTRACT
The research on the disease COVID-19 is an ongoing process since its outbreak as a pandemic. The repurposing of existing approved drugs has received priority attention due to some promising results obtained regarding COVID-19. In this article, some of the important chemical methodologies adopted for the synthesis of umifenovir, (s)-cidofovir, ribavirin, and ruxolitinib have been dis-cussed. The repurposing of these approved drugs has received priority attention due to some promising results obtained regarding COVID-19 and some drugs are under more therapeutic trials. This manuscript has highlighted the synthetic strategies of four heterocyclic-based approved drugs, umifenovir, (s)-cidofovir, ribavirin, and ruxolitinib, repurposed for the treatment of COVID-19. © 2022 Bentham Science Publishers.
Full text:
Available
Collection:
Databases of international organizations
Database:
Scopus
Language:
English
Journal:
Mini-Reviews in Organic Chemistry
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS